Clinical trial starts for prospective ALS treatment co-developed at Scripps Research Experimental drug 3K3A-APC has shown broad brain-protecting effects in animal studies.
December 17, 2021
LA JOLLA, CA An experimental treatment called 3K3A-APC, which was co-developed at Scripps Research and has shown promise against amyotrophic lateral sclerosis (ALS) in preclinical studies, is now being tested in patients with the disease.
The clinical trial, at Macquarie University in Sydney, Australia, will enroll a total of 16 ALS patients, and aims to provide evidence of the experimental treatment's safety and effectiveness against ALS a progressive neurodegenerative disease that is usually fatal and has no cure.
Often called Lou Gehrig's disease (after the famous baseball player who died of it in 1941), ALS is estimated to afflict up to 20,000 people in the United States at any one time. The disorder features the progressive deaths of muscle-controlling neurons, causing weakness and paralysis in muscle groups and ultimately leading to respiratory failure and death. Despite decades of intensive research, scientists still have not identified the precise causes of ALS in its most common, non-inherited form, and, largely for that reason, there is no Food and Drug Administration (FDA)-approved treatment that markedly improves this condition.
I'm very hopeful that 3K3A-APC will benefit these patients in preclinical tests it has displayed remarkable anti-inflammatory, anti-programmed-cell-death, and other cell-stabilizing activities, says John Griffin, PhD, a professor in the Department of Molecular Medicine at Scripps Research whose lab invented 3K3A-APC.
Griffin initially developed and studied 3K3A-APC with University of Southern California (USC) researcher Berislav Zlokovic, MD, PhD. Zlokovic co-founded Houston-based ZZ Biotech, which has taken 3K3A-APC through advanced preclinical and early clinical development and which provides it for this ALS trial.
The 3K3A-APC drug is a modified version of a natural human protein, activated protein C (APC), which works as a powerful anticoagulant and also has neuroprotective properties. To minimize its chances of causing brain bleeding when used as a treatment, Griffin's lab altered APC in a way that removes 90 percent of its anticoagulant effect without removing its other neuroprotective properties.
Preclinical studies by the researchers and their colleagues have found that 3K3A-APC slows disease progression and extends survival in a commonly used mouse model of ALS. The protein appears to have this effect by delaying the activation of inflammation-promoting immune cells in the brain and spinal cord. The molecule also restores the integrity of the special blood-vessel-lining cells that protect the brain and spinal cord from immune cells and other potentially harmful factors in the blood.
The new clinical trial is being led by neurology Professor Dominic Rowe, MD, PhD, at the Macquarie University Centre for Motor Neuron Disease Research, one of the leading ALS research institutions in Australia. The trial is a Phase 2 open label trial (NCT05039268) that will assign 16 ALS patients to one of two doses of the treatment. The principal goal is to demonstrate the safety and tolerability of 3K3A-APC in ALS patients, although the results may also provide preliminary evidence that the treatment slows the ALS disease process.
Translational Medicine Griffin, John
Most recent headlines
05/01/2027
Worlds first 802.15.4ab-UWB chip verified by Calterah and Rohde & Schwarz to be ...
04/08/2026
Dalet, a leading technology and service provider for media-rich organizations, t...
04/07/2026
April 7 2026, 19:00 (PDT) Detective Conan: Fallen Angel of the Highway Opens in...
01/06/2026
January 6 2026, 05:30 (PST) Dolby Sets the New Standard for Premium Entertainment at CES 2026
Throughout the week, Dolby brings to life the latest innovatio...
02/05/2026
Dalet, a leading technology and service provider for media-rich organizations, t...
01/05/2026
January 5 2026, 18:30 (PST) NBCUniversal's Peacock to Be First Streamer to ...
21/04/2026
Cloud-based production isnt going anywhere, and BitFire is doubling down by prov...
21/04/2026
The topic of artificial intelligence has a stranglehold on the sports-video-prod...
21/04/2026
5G is still a hot topic in live event production, and this workflow continues to...
21/04/2026
At the 2026 NAB Show, Ed McGivern, GM and President of Appear US, discusses the ...
21/04/2026
Studio Network Solutions (SNS) has announced an on-premise AI suite designed for...
21/04/2026
Suite Studios has integrated its file-streaming technology into the newly announced Frame.io Drive, a desktop application from Adobe company Frame.io. The colla...
21/04/2026
Net Insight has integrated InSync Technology's FrameFormer into the Nimbra E...
21/04/2026
Fox Sports has selected Appear as a technology partner to support the next phase...
21/04/2026
Diversified has appointed Tyler Affolter as Chief Revenue Officer (CRO) to lead the company's commercial organisation. The appointment follows the firm'...
21/04/2026
Layercake has formalised the integration of Bitmovin's video streaming infra...
21/04/2026
The International Judo Federation (IJF) has extended its distribution partnershi...
21/04/2026
Glookast has launched the Cinnafilm Tachyon plugin for its Media Producer and Me...
21/04/2026
Eutelsat has entered into an agreement with Cadena Tres, a division of Grupo Ima...
21/04/2026
Dolby Laboratories and TV Azteca have partnered to introduce Dolby Atmos immersive audio to free-to-air television broadcasts. The implementation utilises the A...
21/04/2026
FOX Entertainment partnered with Verizon to overcome significant production hurd...
21/04/2026
Osprey Video has announced its technology showcase for the NAB Show 2026, highli...
21/04/2026
Riedel Communications (Booth C4908) introduced a range of new solutions at NAB S...
21/04/2026
The NAB Show is in full swing, and the SVG and SVG Europe editorial teams are chasing down the hottest stories from all over the Las Vegas Convention Center. He...
21/04/2026
Blackmagic Design has announced the URSA Cine Immersive 100G, an immersive cinem...
21/04/2026
Clark Wire & Cable is continuing its evolution from cable supplier to full-scale solutions partner for broadcast and live production. At the 2026 NAB Show, we s...
21/04/2026
Rashad Frett attends the 2025 Sundance Film Festival premiere of Ricky at Eccles Theatre on January 24, 2025, in Park City, UT. (Photo by George Pimentel/Shut...
21/04/2026
Five years ago, Spotify arrived in Pakistan, opening a new chapter in the country's music scene. Since then, local listeners have explored across genres, ge...
21/04/2026
Since its launch in 2020, RADAR has been our program for spotlighting emerging artists around the world. This year marks the sixth edition of RADAR Spain, our o...
21/04/2026
Offers compact wireless solution for pedalboards
Taiwanese audio brand Cloudvocal have announced the availability of a new pedalboard-friendly wireless syst...
21/04/2026
Latest hybrid sampling/synthesis instrument arrives
Arturia's Augmented series offerings rely on a mixture of sampling and synthesis, allowing users to ...
21/04/2026
Rohde & Schwarz to host Power Electronics Online Conference From Design to Vali...
21/04/2026
MAS and Lockheed Martin partner to establish an F-35 depot in Canada, enabling in-country sustainment and creating high-skilled aerospace jobs....
21/04/2026
Advertising strategies shift as competition grows for a large, active and qualit...
21/04/2026
Share
Copy link
Facebook
X
Linkedin
Bluesky
Email...
21/04/2026
Share
Copy link
Facebook
X
Linkedin
Bluesky
Email...
21/04/2026
Share
Copy link
Facebook
X
Linkedin
Bluesky
Email...
21/04/2026
Share
Copy link
Facebook
X
Linkedin
Bluesky
Email...
21/04/2026
Share
Copy link
Facebook
X
Linkedin
Bluesky
Email...
21/04/2026
Share
Copy link
Facebook
X
Linkedin
Bluesky
Email...
21/04/2026
Share
Copy link
Facebook
X
Linkedin
Bluesky
Email...
21/04/2026
Share
Copy link
Facebook
X
Linkedin
Bluesky
Email...
21/04/2026
Layercake Deepens Bitmovin Integration to Power End-to-End Media Orchestration w...
21/04/2026
Cobalt Digital Announces Launch of blueCORE at NAB Show 2026: Compact Powerhouse...
21/04/2026
On-Premise AI Suite from Studio Network Solutions Debuts at NAB Show 2026
Melanie Ciotti April 21, 2026
0 Comments
Unlimited processing, no cloud depe...
21/04/2026
London, 21 April 2026 IBC today announced the appointment of Tim Banham as its first Chief Commercial Officer (CCO), a newly created role that reflects the or...
21/04/2026
Motion Design Tools - April 2026
Roland Kahlenberg April 21, 2026
0 Comments
Within 2 days, Maxon and Canva announced pro-level motion design apps - A...
21/04/2026
Chaos and Zero Density to Showcase Real-Time Ray Tracing for Virtual Studios and...
21/04/2026
Share
Copy link
Facebook
X
Linkedin
Bluesky
Email...
Clinical trial starts for prospective ALS treatment co-developed at Scripps Research Experimental drug 3K3A-APC has shown broad brain-protecting effects in animal studies. 
